IRVINE, Calif.--(BUSINESS WIRE)--Nov. 2, 2018--
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a
medical technology company focused on the design, development and
commercialization of innovative and minimally invasive sacral
neuromodulation (“SNM”) solutions for the treatment of overactive
bladder (“OAB”), fecal incontinence (“FI”), and urinary retention
(“UR”), today announced the closing of its initial public offering of
8,000,000 shares of common stock at an initial public offering price of
$15.00 per share, raising $120 million in gross proceeds from the
offering, before underwriting discounts and commissions and estimated
offering expenses. Axonics has also granted the underwriters a 30-day
option to purchase an additional 1,200,000 shares of common stock at the
initial public offering price, less underwriting discounts and
commissions. All of the shares of common stock were offered by Axonics.
Axonics’ common stock began trading on The Nasdaq Global Select Market
under the ticker symbol “AXNX” on October 31, 2018.
BofA Merrill Lynch and Morgan Stanley acted as joint book-running
managers for the offering. Wells Fargo Securities acted as lead manager
and SunTrust Robinson Humphrey acted as co-manager for the offering.
A registration statement on Form S-1, including a prospectus relating to
the offering, has been filed with, and declared effective by, the U.S.
Securities and Exchange Commission on October 30, 2018. The offering of
these shares was made only by means of a prospectus. Copies of the
prospectus may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email at dg.prospectus_requests@baml.com;
or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Axonics Modulation Technologies, Inc.
Axonics has developed an innovative rechargeable SNM system for the
treatment of patients with OAB, FI, and UR. Axonics’ proprietary r-SNM
System is designed to be 60% smaller than existing technology and to
last approximately 15 years. Axonics currently has marketing approvals
in Europe, Canada, and Australia for OAB, FI, and UR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005400/en/
Source: Axonics Modulation Technologies, Inc.
Axonics’ Contacts
Axonics Modulation Technologies, Inc.
Dan
Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com
or
Investor
& Media Contact
W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com
